Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REST: Isatuximab + VRd in NDMM
NCT04939844Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Jun 2021
- Primary completion
- Aug 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of isatuximab in multiple myeloma (MM), sponsored by Oslo University Hospital. Started Jun 2021; status: completed.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04939844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939844.